3.

EGFR 19和21外显子突变患者病理生理特征的比较

Comparison of clinical significance between EGFR exon 19 mutation groups and EGFR exon 21 mutation groups

Characteristic		EGFR mutation		χ2	P
		Exon 19 (n=56)	Exon 21 (n=57)
**The differentiation of one patient with EGFR exon 19 mutation and 6 patients with EGFR exon 21 mutation is not defined in this study.
Primary site	Left side	19 (33.9%)	30 (52.6%)	4.023	0.045
	Right side	37 (66.1%)	27(47.4%)
Histology	Adenocarcinoma	45 (80.4%)	50 (87.7%)	1.264	0.738
	SCC	4 (7.1%)	2 (3.5%)
	Ad-SCC	4 (7.1%)	3 (5.3%)
	Others	3 (5.4%)	2 (3.5%)
Differentiation**	Well	32 (57.1%)	25 (43.9%)	0.953	0.621
	Moderately	17 (30.4%)	20 (35.1%)
	Poorly	6 (10.7%)	6 (10.5%)
TNM staging	Ⅰ	19 (33.9%)	12 (21.1%)	2.627	0.453
	Ⅱ	6 (10.7%)	9 (15.8%)
	Ⅲ	20 (35.7%)	22 (38.6%)
	Ⅳ	11 (19.6%)	14 (24.6%)